Efficacy of sulfamethoxypyridazine in a murine model of Pneumocystis carinii pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 4, 1998, Pages 934-935

  Bartlett, Marilyn S ^a   Shaw, Margaret M ^a   Smith, James W ^a   Meshnick, Steven R ^b  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DRINKING WATER; SULFAMETHOXAZOLE; SULFAMETHOXYPYRIDAZINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL MODEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; EXPERIMENTAL MODEL; NONHUMAN; NOTE; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL;

EID: 0031956395     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.4.934     Document Type: Note

References (17)

1. Anand, N. 1980. Sulfonamides and sulfones, p. 1-40. In M. Wolff (ed.), Burger's medicinal chemistry. Wiley Interscience, New York, N.Y.
2. Bartlett, M. S., S. F. Queener, M. M. Durkin, M. M. Shaw, and J. W. Smith. 1992. Inoculated mouse model of Pneumocystis carinii infection. Diagn. Microbiol. Infect. Dis. 15:129-134.
3. Björkman, A., and P. A. Phillips-Howard. 1991. Adverse reactions to sulfa drugs: implications for malaria chemotherapy. Bull. W. H. O. 69:297-304.
4. Cortese, L. M., D. M. Soucy, and T. P. Endy. 1996. Trimethoprim/sulfamethoxazole desensitization. Ann. Pharmacother. 30:184-186.
5. Cribb, A. E., B. L. Lee, L. A. Trepanier, and S. P. Spielberg. 1996. Adverse reactions to sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React. Toxicol. Rev. 15:9-50.
6. Funk, K. F. 1970. Pharmakokinetische Modelluntersuchungen an der Ratte. Das Einkammer-Modell des Organismus. Acta Biol. Med. Germ. 25:151-160.
7. Hong, Y.-L., P. A. Hossler, M. S. Bartlett, S. F. Queener, J. W. Smith, and S. R. Meshnick. 1996. Evaluation of sulfa drugs against the Pneumocystis carinii dihydropteroate synthetase and in vivo. J. Eukaryot. Microbiol. 43: 40S.
8. Hong, Y.-L., P. A. Hossler, D. H. Calhoun, and S. R. Meshnick. 1995. Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob. Agents Chemother. 39:1756-1763.
9. Hoover, D. R., A. J. Saah, and H. Bacellar, et al. 1993. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N. Engl. J. Med. 329: 1922-1926.
10. Hughes, W. T., and J. Killmar. 1996. Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 40:962-965.
11. Hughes, W. T., and J. Killmar. 1997. Is trimethoprim of trimethoprimsulfamethoxazole (TMP-SMX) necessary for Pneumocystis carinii pneumonia (PCP) prophylaxis?, abstr. 289, p. 117. In Program and Abstracts of the Fourth Congress on Retroviruses and Opportunistic Infections, Washington, D.C.
12. Kunz, S., U. Junker, and J. Blaser, et al. 1995. The seid mouse as an experimental model for the evaluation of anti-Pneumocystis carinii therapy. J. Antimicrob. Chemother. 36:137-155.
13. Lane, B. R., J. C. Ast, P. A. Hossler, D. P. Mindell, M. S. Bartlett, J. W. Smith, and S. R. Meshnick. 1997. Dihydropteroate synthase polymorphisms in Pneumocystis carinii. J. Infect. Dis. 175:482-485.
14. Rallison, M. L., J. O'Brien, and R. Good. 1966. Severe reactions to long-acting sulfonamides. Pediatrics 28:908-917.
15. Salvaggio, J., and F. Gonzalez. 1959. Severe toxic reactions associated with sulfamethoxypyridazine (Kynex). Ann. Intern. Med. 41:60-67.
16. Simonds, R. J., W. T. Hughes, J. Feinberg, and T. R. Navin. 1995. Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus. Clin. Infect. Dis. 21(Suppl. 1):S44-S48.
17. Walzer, P. D., J. Foy, P. Steele, C. K. Kim, M. White, R. S. Klein, B. A. Otter, and C. Allegra. 1992. Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 36:1935-1942.